Clostridium difficile is the infectious agent responsible for antibiotic-associated colitis. We report the use of the polymerase chain reaction technique to identify toxigenic strains of C. dJficile in human stool specimens. A set of primers based on the nucleotide sequence of the toxin B gene, which amplified a 399-bp fragment from isolates producing toxin B, was designed. We examined 28 known toxigenic strains, which were all positive by this assay. DNAs from the nontoxigenic strains examined and from strains of Clostridium sordeUii and C. bifermentans were not amplified with these primers. The sensitivity of this assay allowed us to identify as little as 10%X toxigenic C. difficile cells in the presence of 90%o nontoxigenic cells and to detect the toxin B gene in 1 pg of DNA from a toxigenic strain. DNAs extracted from 18 clinical stool specimens that were positive for toxin B by the tissue culture cytotoxicity assay were also positive by this assay. In addition, we detected toxin B sequences in DNA from 2 of 18 stool specimens that were negative for toxin B by the cytotoxicity assay. These two stool specimens were from patients who had a clinical pattern of colitis that was compatible with C. difficile causation. This rapid, sensitive assay will be useful for specific identification of toxigenic C. dijfficile and for revealing cases that are undetected by analysis of fecal samples for toxin B alone.
Diagnosis of C. difficile-induced colitis is made by testing
for the presence of toxins A and B in fecal specimens. The toxin B assay is a fibroblastic tissue culture assay in which cytopathologic effects are observed after the addition of stool filtrates rendered free of bacteria to the cultured cells. Many hospitals lack the facilities to perform this assay; in addition, it has a 5% false-negative rate because of toxin degradation by naturally occurring proteases present in feces or instability with storage (freezing and thawing). Clinical tests specific for toxin A include a dot immunobinding assay and several enzyme immunoassays. These tests, although simple to perform, do not detect strains of C. difficile that produce low levels of toxin and thus occasionally give indeterminate results.
Recently, the toxin B gene from C. dificile was cloned and sequenced (1, 8, 17) . This has allowed the application of the polymerase chain reaction (PCR) technique for the detection of toxigenic strains of C. difficile (19) . Others have developed PCR-based assays to detect toxin A sequences in strains of C. difficile (9, 20) . These PCR-based toxin studies have only been performed on DNA from C. difficile grown in cultures and have not been applied to clinical specimens. However, the PCR was previously used by us to detect the rRNA gene of C. difficile (toxigenic and nontoxigenic strains) directly in human fecal samples (6) .
In this study, we report the use of PCR to identify toxigenic strains of C. difficile directly in the stool of patients. The specificity and sensitivity of our PCR tech-* Corresponding author.
nique in detecting toxigenic strains of C. difficile in a mixed population with nontoxigenic strains were determined. This assay may be useful in rapidly identifying infected patients and can contribute to more timely therapeutic intervention for patients.
MATERIALS AND METHODS
Bacterial strains and culture media. The C. difficile strains used in this study were isolates from patients at the University of California, Davis Medical Center (28 toxigenic strains and 22 nontoxigenic strains). The toxigenic strains showed various degrees of toxigenicity, including weak toxigenicity. Clostridium sordellii (Centers for Disease Control), C. bifermentans (ATCC 638), and Escherichia coli (University of California, Davis Medical Center) were also used. C. difficile was cultured from stool specimens on plates of cycloserinecefoxitin-fructose-agar, a medium highly selective for C. difficile (5 No amplification products were observed with DNA from nontoxigenic strains (Fig. 1A) . To confirm the specificity of the product, Southern blot analysis was done with a biotinlabeled internal probe, YT-20. As seen in Fig. 1B , only DNA products from toxigenic strains hybridized with the probe. None of the nontoxigenic strains probed positive.
Specificity of the PCR assay. To further determine the specificity of the PCR assay, amplification reactions were carried out with DNA from four strains of C. sordellii and one strain of C. bifermentans. These species were selected because they are closely related to C. difficile and because it is well documented that the hemorragic toxin protein of C. sordellii cross-reacts with toxin A of C. difficile in antibodybased assays (11) . Some PCR-based techniques have also resulted in cross-reactivity between these two species (6, 20) . No amplification products were obtained with DNAs from the strains of C. sordellii tested in this study ( Fig. 2A) , and these samples remained negative when probed with the internal probe (Fig. 2B) .
Sensitivity of toxin B PCR assay. Before the sensitivity of our PCR assay was determined, experiments were done to determine the optimal MgCl2 concentration for the primer pair YT-17 and YT-18. For this purpose, our PCR buffer was supplemented with MgCl2 concentrations ranging from 0.5 to 4 ,uM. Amplification reactions were set up with DNA amounts ranging from 10 to 100 ng. With the lower amounts of DNA, more efficient amplification was obtained with MgCl2 concentrations of 2.5 ,uM. This concentration was then used in the sensitivity experiments.
The sensitivity of this system in detecting toxigenic strains of C. difficile was determined with two experiments. In the first experiment, DNA from C. difficile in amounts equal to those found in 10 to 104 cells was mixed with E. coli DNA equal to the amount in 106 cells. After 40 cycles of amplification, as few as 100 cells of C. difficile could be detected among 106 cells of E. coli (Fig. 3) . The second experiment was designed to detect the sensitivity of our technique in detecting toxigenic strains of C. difficile in a mixed popula- tion with nontoxigenic strains. This would allow specific identification of toxigenic strains in patients colonized by more than one strain of C. difficile. For these experiments, we mixed DNA from a toxigenic strain in ratios that varied from 10 to 50% with DNA from a nontoxigenic strain in ratios of 90 to 50%, respectively. In a mixed population, as little as 10% toxigenic bacteria could be detected by our technique (data not shown).
Amplification of clinical specimens. Extracting DNA from stool specimens results in much variability from specimen to specimen in the yield and purity of DNA obtained. In addition, it has been reported that clinical specimens (stool and urine) contain inhibitors of DNA polymerase (18) . As a control for amplifiable clostridial DNA extracted from stool, the DNA was amplified with the 16S rRNA primers B and PG-48 (6). Only specimens from which DNA amplification was obtained with the rRNA primers were screened with the toxin B PCR assay. Approximately 90% of the symptomatic patient specimens we studied were positive for the clostridial 16S rRNA amplicon. All 18 specimens that tested negative in the toxin B PCR assay tested negative in the cytotoxicity assay. All specimens that were positive for toxin B by the tissue culture assay were also positive by the PCR; the data for some of these are shown in Fig. 4 . Toxin B gene amplification products were also produced from DNA extracted from two stool specimens of symptomatic patients which were reported negative by the cytotoxicity assay. These patients had a clinical pattern of colitis compatible with C. difficile causation, had been on antibiotic therapy for several days, had previous histories of C. difficile relapses for periods of 3 to 9 months, and had all of the symptoms characteristic of antibiotic-associated colitis.
DISCUSSION
This report outlines the use of PCR to identify toxigenic strains of C. difficile by amplification of toxin B gene sequences directly from the stools of human patients. The PCR has been used previously by several investigators to identify toxigenic strains of C. difficile (12, 13, 19, 20 (3, 15) .
The sensitivity of our assay in detecting toxigenic strains of C. difficile in a mixed population with nontoxigenic strains was determined. This would be of importance for patients colonized by more than one strain of C. difficile. Toxigenic and nontoxigenic isolates have been cultured concurrently from the stools of individual patients, indicating that more than one strain of C. difficile can be harbored simultaneously (2) . Conventional tests require the isolation and testing of a number of separate colonies obtained from the same stool specimen to determine whether more than one strain of C. difficile is present. Although the experiments presented in this study were done in vitro with different DNA concentrations from a toxigenic and a nontoxigenic strain, we speculate that the toxin B PCR assay in conjunction with the 16S rRNA PCR assay can be applied to identify colonization of an individual patient with toxigenic or nontoxigenic C. difficile or both (6) 
